A61P 7 - Drugs for disorders of the blood or the extracellular fluid

Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
10/2002
10/24/2002	US20020156102 Piperidine amides as modulators of chemo kine receptor activity
10/24/2002	US20020156081 Pyrazolopyrimidines as therapeutic agents
10/24/2002	US20020156007 Apolipoprotein analogues
10/24/2002	US20020156000 Inhibiting NF-kappa B-dependent target gene expression in a cell.
10/24/2002	US20020155597 In vivo production and delivery of erthropoietin or insulinotropin for gene therapy
10/24/2002	US20020155528 Regulation of human CysLT2-like GPCR protein
10/24/2002	US20020155432 Genetically engineered herpes virus for the treatment of cardiovascular disease
10/24/2002	US20020155115 Cancer therapy
10/24/2002	US20020155107 Methods and formulations for reducing circulating antibodies
10/24/2002	US20020155091 For reducing serum cholesterol in a mammal
10/24/2002	DE10119905A1 Enriching intermediates in the mevalonate-independent pathway of isoprenoid synthesis, useful for therapeutic activation of T cells, comprises altering enzymatic activity in the pathway
10/24/2002	CA2763637A1 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
10/24/2002	CA2444247A1 Inhibitors of integrin .alpha.v.beta.6
10/24/2002	CA2443897A1 Transporters and ion channels
10/24/2002	CA2443805A1 Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
10/24/2002	CA2443709A1 Novel cyclo azaphospha hydrocarbons
10/24/2002	CA2443699A1 Phenyl heterocyclyl ether
10/24/2002	CA2443568A1 Novel pyridine- and cyclohexenyl-comprising pyrrolobenzodiazepi ne-carboxamides and derivatives thereof; tocolytic oxytocin receptor antagonists
10/24/2002	CA2443565A1 Novel cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
10/24/2002	CA2443487A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/24/2002	CA2443468A1 Pharmaceutical product with reticulated crystalline microstructure
10/24/2002	CA2443408A1 Kinases and phosphatases
10/24/2002	CA2443244A1 Enzymes
10/24/2002	CA2443234A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/24/2002	CA2442729A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/24/2002	CA2438107A1 G-protein coupled receptor molecules and uses thereof
10/24/2002	CA2431553A1 Cxcr3 antagonists
10/23/2002	EP1251176A2 Expression systems utilizing autolyzing fusion proteins and a reducing polypeptide
10/23/2002	EP1251128A1 Cyclohexylamine derivatives as subtype selective N-methyl-D-aspartate antagonists
10/23/2002	EP1250422A2 Myeloid colony stimulating factor and uses thereof
10/23/2002	EP1250328A1 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
10/23/2002	EP1250155A1 Angiogenesis and vascular permeability modulators and inhibitors
10/23/2002	EP1250154A2 G-csf conjugates
10/23/2002	EP1250142A1 Multivalent electron active compositions and methods of making and using same
10/23/2002	EP1250141A1 Prevention and treatment of endotoxemia and related complications associated with surgery
10/23/2002	EP1250140A2 Combinations of a receptor tyrosine kinase inhibitor with alpha1-acidic glycoprotein binding compound
10/23/2002	EP1250116A1 Pharmaceutical and cosmetic carrier or composition for topical application
10/23/2002	EP1250092A1 Novel dyes
10/23/2002	EP1150702B1 Use of orosomucoid for the production of a pharmaceutical preparation for the treatment of pancreatitis
10/23/2002	EP0783499B1 Benzofuran derivatives as tachykinin antagonists
10/23/2002	CN1376150A Drug compositions exhibiting thrombo poietin agonism
10/23/2002	CN1376144A Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
10/23/2002	CN1375209A Healthy tea
10/23/2002	CN1093125C Sulfamide-metalloprotease inhibitors
10/23/2002	CA2383149A1 Process for partially reducing or eliminating the symptoms associated with the release of histamine in the body
10/22/2002	US6469162 Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy and diagnosis
10/22/2002	US6469062 Use of 15-keto-prostaglandins in promoting bile secretion
10/22/2002	US6469056 Pharmaceutically active compounds, their preparation and use as ECE-inhibitors
10/22/2002	US6469054 Aryl sulphonamides and analogues
10/22/2002	US6469045 Thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products; oral administration
10/22/2002	US6469029 Azacycloalkanone serine protease inhibitors
10/22/2002	US6469026 For therapy and prophylaxis of conditions in mammals characterized by undesired thrombosis
10/22/2002	US6469025 For the prophylaxis or treatment of a disease or disorder in a mammal in which the extravasation of leukocytes plays a role; inhibiting the binding of alpha 4 integrins to their ligands
10/22/2002	US6469018 Compounds
10/22/2002	US6469011 Benzenesulfonamide compounds useful as TXA2 and 5-HT2 receptor antagonists
10/22/2002	US6468986 Composition comprising polynucleotide and polycationic agent which exhibits net positive electrical charge at physiological ph, and is capable of mediating entry of polynucleotides into cell
10/22/2002	US6468974 Oligopeptides that provide desirable in vitro and in vivo growth hormone releasing activity and have at least one other desirable biological activity such as increased retention time
10/22/2002	US6468778 Process for the inactivation of viruses
10/22/2002	US6468527 Biological bioadhesive composition and methods of preparation and use
10/22/2002	US6468519 Polyanhydrides with biologically active degradation products
10/22/2002	US6468507 Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
10/22/2002	CA2216437C Pharmaceutical composition containing selected lanthanum carbonate hydrates
10/22/2002	CA2185712C Enhanced virus-mediated dna transfer
10/22/2002	CA2118670C Pharmaceutical compositions in semisolid form and a device for administration thereof
10/17/2002	WO2002082091A2 Method for identification of proteins from intracellular bacteria
10/17/2002	WO2002081728A2 Quinoline inhibitors of hyak1 and hyak3 kinases
10/17/2002	WO2002081681A1 Novel use of cytokine sf20
10/17/2002	WO2002081499A2 Somatostatin agonists
10/17/2002	WO2002081475A1 Jun kinase inhibitors
10/17/2002	WO2002081467A1 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
10/17/2002	WO2002081449A1 Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
10/17/2002	WO2002081448A1 Benzamidine derivative
10/17/2002	WO2002081443A1 Novel guanidino compounds
10/17/2002	WO2002080987A1 Anti-cd19 immunotoxins
10/17/2002	WO2002080979A2 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002	WO2002080955A1 Stimulation of osteogenesis using rank ligand fusion proteins
10/17/2002	WO2002080926A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002	WO2002080914A2 Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments
10/17/2002	WO2002080905A1 Kappa opiate agonists for the treatment of bladder diseases
10/17/2002	WO2002080900A1 Method for improving the well-being of poultry by in-ovo injection of carnitine
10/17/2002	WO2002080887A2 Timed pulse release composition
10/17/2002	WO2002080853A2 Fused heterocyclic inhibitors of factor xa
10/17/2002	WO2002072619A8 INTEGRIN αIIbβ3 ACTIVATING PEPTIDES AND THEIR USE
10/17/2002	WO2002029061A3 G-protein coupled receptors
10/17/2002	WO2002026712A3 Quaternary amines and related inhibitors of factor xa
10/17/2002	WO2002017891A3 Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency
10/17/2002	WO2002010192A9 Somatostatin analogues
10/17/2002	WO2001098323A3 G-protein coupled receptors
10/17/2002	WO2001077378A3 Diagnosis of diseases associated with dna adducts
10/17/2002	US20020151724 Such as 1-((4-methoxybenzoyl-D-phenylglycinyl))-4-((isopropylamino)methyl)piperidine hydrochloride as anticoaggulants useful in the treatment of cardiovascular disorders such as thrombosis
10/17/2002	US20020151574 Extracellular signal regulated kinase (ERK); anticancer agents and protein kinase inhibitors
10/17/2002	US20020151545 Anticoagulants in treating and preventing cardiovascular diseases, as anti-inflammatory agents, and metastasis inhibitors in treating cancer
10/17/2002	US20020151501 Compounds having growth hormone releasing activity
10/17/2002	US20020151488 G-CSF analog compositions and methods
10/17/2002	US20020151469 Low oxygen affinity mutant hemoglobins
10/17/2002	US20020151468 Low oxygen affinity mutant hemoglobins
10/17/2002	US20020151049 Self-enhancing, pharmacologically controllable expression systems
10/17/2002	US20020151009 Human polynucleotides, polypeptides, and antibodies
10/17/2002	US20020150888 Methods of screening for modulators of HIV infection
10/17/2002	US20020150624 Mixture of drug, aminoacrylate polymer and acid

1 ... 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 ... 671